U.S. Markets closed

Krystal Biotech, Inc. (KRYS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
70.78+0.37 (+0.53%)
At close: 4:00PM EDT
Sign in to post a message.
  • B
    BagholderHumper
    This morning's news:

    "...the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 11-14, 2021. Data to be presented includes evidence of in vitro molecular efficacy with KB501 (expressing a TNF-α targeting antibody), and in vivo proof-of-concept in two models of atopic dermatitis with KB501 and KB502 (expressing an IL-4Rα targeting antibody).

    'The ability to deliver sustained antibody expression locally in the target tissue of interest opens up exciting new strategic optionality for our platform,” said Suma Krishnan, founder and chief operating officer of Krystal Biotech. “This approach holds the potential to transform the management of chronic conditions where redosability is critical and limiting systemic exposure is desirable from a safety or tolerability perspective.'"

    Steady progress.
  • B
    BagholderHumper
    Could be very, VERY important:

    "PITTSBURGH, April 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced positive results of its IND-enabling good laboratory practice (GLP) toxicology study of KB407, an inhaled gene therapy candidate for the treatment of cystic fibrosis (CF), in nonhuman primates (NHPs). In addition, the Company announced initial preclinical proof-of-concept for its second genetic pulmonary disease candidate, KB408, for the treatment of alpha-1 antitrypsin deficiency (AATD).

    “Successful completion of this GLP toxicology and biodistribution study is an important milestone not only for KB407, but also for our emerging pulmonary portfolio,” said Suma Krishnan, founder and chief operating officer of Krystal Biotech. “We are excited to expand our pulmonary pipeline with the addition of KB408 for the potential treatment of alpha-1 antitrypsin deficiency and look forward to continued progress with our additional discovery phase candidates.”
  • m
    matt
    I guess I'll join you on here. Whats the story with this company? I bought 175 shares at $81.50. Does it have a chance to go to $100 by July, in your opinion?
  • B
    BAGHOLDER HUMPER
    Up almost 30% before noon! Next objective is $30!
  • B
    BAGHOLDER HUMPER
    Nice move on good volume...very promising.
  • C
    Crecy
    Does the company own the patent on their modified HSV-1?
  • H
    Harry
    Blair puts a buy rating on the stock after Chardan and Ladenburg (trifecta of lower tier banks). This stock doesn't trade enough to generate commission dollars. There must be a stock offering in the works.
  • B
    BAGHOLDER HUMPER
    Oh, MY!!! LOOK! It's up TWENTY TWO PERCENT now!!! Flying like an EAGLE! ROFLMAO!
  • n
    necmi
    This will take at least 25-30% hair cut tomorrow because of the financing announcement. Great trial results- significant price appreciation-management anouncement of stock offering to raise funds is classic in biotech.
  • n
    necmi
    Krys is way overvalued given phase III has not even begun and other assets in the pipeline are starting Phase 1. Agree with post by "Anonymous" that many Phase II successes have turned out Phase III failures in biotech.
    It went up with low volume due to momentum, but when funds and institutions start selling for profit taking and/or end of month window dressing it will spiral down big and fast.
  • n
    necmi
    I was long on this until price hit mid thirties.They have not even started Phase 3 for the rare skin disease indication, will need to raise funds soon, and rest of the indications are pre-clinical. Current share price is way exuberant and overvalued and any negative news will trigger a huge haircut. I have to give credit to those who successfully hyped this stock.
  • J
    Jerry
    will come down to less than $35 tomorrow after the $100m offering
  • a
    ark1
    Just announced $100m offering of common stock :(
  • a
    agave
    I sold today. First the company introduced a new candidate for cystic fibrosis, the tells us they are being sued for IP covering ENTIRE backbone, then they issue about $100 million new shares, the Krish sells a lot. The pipeline looks good, but this company doesn't pass the smell test any more.
  • B
    BAGHOLDER HUMPER
    Closed UP almost TWENTY FOUR percent! I'm so HAPPY, I can't stop DANCING! ROFLMAO!!!
  • B
    BAGHOLDER HUMPER
    KRYS presented at two conferences the past two days:

    B. Riley FBR Annual Healthcare Investor Conference
    Date: Tuesday, September 4
    Time: 12:50 – 1:50 p.m. EDT (panel discussion)
    Location: New York Marriott

    H.C. Wainwright 20th Annual Global Investment Conference
    Date: Wednesday, September 5
    Time: 3:50 - 4:15 p.m. EDT

    Today's reaction suggests a least some positive response, although I'm hoping for volume to build throughout the day.
  • a
    agave
    Latest foray into CFTR and other pulmonary diseases with KB407 represents a departure from primarily focus on monogenic skin diseases. The stock should rise substantially by end of this year when investors realize the huge success likely in this area.
  • B
    BAGHOLDER HUMPER
    VERY interesting -- private placement:

    https://finance.yahoo.com/news/krystal-biotech-announces-10-million-231703303.html

    ...625,000 shares with no warrants or other strings attached. Frazier has a pretty impressive history of investing:

    https://www.frazierhealthcare.com/portfolio#?sector=pharmaceuticals
    Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has entered into a securities purchase agreement with Frazi
    Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has entered into a securities purchase agreement with Frazi
    finance.yahoo.com
  • B
    BAGHOLDER HUMPER
    Good volume again with nice move upward to new all time high -- makes me happy.